Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's John Harter

Executive Summary

Pilot Drug Evaluation Staff former director, in valedictory speech before the Arthritis Drugs Advisory Committee Jan. 28, tells the group he has "been reassigned out of the commission" to a new office and that it is "clear the management would prefer that I didn't [remain involved] with rheumatology." A memo of a Jan. 7 PDES staff meeting states that Harter is being offered "a new position in the Office of Research Resources with collateral responsibilities in [FDA's] Staff College" ("The Pink Sheet" Jan. 24, T&G-2). Responding to the announcement, committee Chair George Ehrlich, MD, University of Pennsylvania, expressed his "personal regrets" over Harter's reassignment, saying he hopes "it will be reversed." Harter sees the brighter side: "I'm not sure that's the way to look at it, George. Whenever there's a change it's an opportunity to improve the process somehow." Harter spent the majority of time discussing his brainchild, the "NDA Day"

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel